This is a highly significant development. Phase 2 metabolism is...

This is a highly significant development.

Phase 2 metabolism is a major impediment to effective cancer treatment, causing otherwise-promising drugs to become ineffective in the body. It looks like Noxopharm has now created two ways to overcome it.

We already know that if Idronoxil is dissolved within a carrier base and then delivered by suppository, it is able to avoid Phase 2 metabolism and as a result, its half-life increases from 45 minutes to more than 10 hours. In other words, it remains in the body in an active state long enough to work its magic.

It sounds like Noxopharm chemists have worked out how to emulate this effect and have then been able to attach their creation to other compounds they have created, with stunning results. If the new drugs are highly active against pancreatic and gallbladder cancer, just imagine the range of other cancers that might be vulnerable to this breakthrough technology.